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Background: Asthma is a chronic inflammatory disorder of the airways with the proven role of Th2 cells in its
pathogenesis. The role and characteristic of different subsets of CD4+ cells is much less known.
Aim: The aim of the study was to analyze the incidence of different subsets of CD4+ T cells, in particular different
subsets of CD4+ cells with the co-expression of different cytokines.
Methods: Twenty five stable asthmatic and twelve age-matched control subjects were recruited to the study.
Bronchoscopy and bronchoalveolar lavage (BAL) were performed in all study subjects. CD4+ T cells were isolated
from BAL fluid by positive magnetic selection. After stimulation simultaneous expression of TGF-β, FoxP3, CD25,
IFN-γ, IL-4, TNF-α (set 1); IL-10, FoxP3, CD25, IFN-γ, IL-4, MIP-1β (set 2); IL-17A, IL-8, IFN-γ, IL-4, MIP-1β (set 3) were
measured by flow cytometry.
Results: The percentage of CD4+ cells co-expressing Foxp3 and TGF-β (CD4+Foxp3+TGF-β+ cells) was significantly
lower (P = 0.03), whereas the percentage of CD4+IL-17+ cells (P = 0.008), CD4+IL-17+ IFN-γ+ cells (P = 0.047) and
CD4+IL-4+ cells (P = 0.01) were significantly increased in asthmatics compared with that seen in healthy subjects. A
significantly higher percentage of CD4+Foxp3+ cells from asthma patients expressed IFN-γ (P = 0.01), IL-4 (P = 0.004)
and CD25 (P = 0.04), whereas the percentage of CD4+IL-10+ cells expressing Foxp3 was significantly decreased in
asthmatics (P = 0.03). FEV1% predicted correlated negatively with the percentage of CD4
+IL-17+ cells (r = -0.33;
P = 0.046) and positively with CD4+Foxp3+TGF-β+ cells (r = 0.43; P = 0.01).
Conclusions: Our results suggest that in the airways of chronic asthma patients there is an imbalance between
increased numbers of CD4+IL-17+ cells and Th2 cells and decreased number of CD4+Foxp3+TGF-β+.
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Asthma is a chronic inflammatory disorder of the airways
characterized by variable airflow obstruction and presence
of airway hyperresponsiveness that leads to typical symp-
toms like recurrent episodes of wheezing, breathlessness,
chest tightness and coughing [1]. CD4+ T cells are one of
the most important cells in the pathogenesis of airway in-
flammation in asthma. CD4+ T cells are traditionally di-
vided into Th1 and Th2 subsets based on profile of their* Correspondence: ian.adcock@imperial.ac.uk
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unless otherwise stated.cytokines production [2,3]. Th2 cells, which are character-
ized by IL-4, IL-5, IL-9 and IL-13 cytokine production,
predominate in asthma, whereas Th1 cells producing IFN-
γ, IL-2 and TNF have rarely been associated with asthma
[2,3]. More recently new subsets of CD4+ T cells have
been described: anti-inflammatory (suppressive) T regula-
tory (Treg) cells and proinflammatory Th17 cells [2,3].
CD4+ Treg cells can be divided into natural regulatory
T cells (nTreg cells) and inducible or adaptive regulatory
T cells (iTreg cells) [4]. nTreg got their name because
they are always present in the body and constantly per-
form their function during normal surveillance of self-
antigens [4]. They arise in thymus and leave it fullyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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constitute the population of long-living cells, resident in
peripheral organs and one of their main activities is pro-
tection against autoimmunological disorders [4]. The
first described marker of these cells was CD25 with a
more recent marker of nTreg cells being the constitu-
tively expressed transcription factor Foxp3 [4]. There-
fore CD4+Foxp3+ or CD4+CD25+Foxp3+ cells are often
regarded as nTreg cells, in spite of the fact that newer
markers have also been proposed [5]. However it should
be noted that we still lack precise and specific markers
of nTreg cells [6].
iTreg, in contrast to nTreg, obtain their regulatory
ability in peripheral tissues. Naïve or mature CD4+ cells
are activated by dendritic cells in the secondary lymph-
oid organs [7]. The main function of iTreg is therefore
to counteract excessive or the pathological inflammatory
response [7,8]. There are no good surface markers of
iTreg and according to some authors they lack CD25
expression (CD4+CD25- cells) [8] whereas others have
shown that CD4+CD25+ iTreg can be generated from
naïve CD4+ cells after antigen stimulation in the pres-
ence of IL-2 and TGF-β [9]. Furthermore it was shown
that TGF-β-induced iTreg cells may express Foxp3 [10]
and that Foxp3+ Treg cells are a rich source of TGF-β
[11-13]. These latter cells are also known as Th3 cells.
Phenotypic characterization of Th3 cells is very difficult
as not all TGF-β-secreting T cells are Th3 cells and not
all Th3 cells express Foxp3 [11-13].
Tr1 cells are another subset of iTreg cells, which is
difficult to study in great details as we still lack precise
markers, which could help us to reliably distinguish IL-
10-secreting Treg cells from other T cells [14]. Tr1 cells
produce IL-10, TGF-β and little or no IL-2, IL-4 and can
be sometimes defined as: IL-10+IL-5+IL-4-IL-2+/-IFN-γ+.
Many studies have demonstrated that IL-10-secreting
T cells did not express Foxp3 [15-17] but there are also re-
ports of subsets of Foxp3-expressing Treg cells with the
ability to secrete IL-10 [18,19]. Phenotypic characterization
of Tr1 cells could be therefore defined as CD4+IL-10+IL-4-.
The percentage of CD4+CD25high cells was decreased
in bronchoalveolar lavage (BAL) fluid of pediatric asthma
patients [20]. Also Foxp3 protein expression was decreased
within blood CD4+CD25high cells [21]. However, Smith
et al. have recently shown an increased percentage of
CD4+Foxp3+ and CD4+CD25+CD127- cells in BAL fluid
of moderate to severe asthma [22]. In another study the
percentage of CD4+Foxp3+ cells in BAL increased after al-
lergen provocative test in asthmatic patients [23].
Th17 cells are a new population of proinflammatory
CD4+ T cells which are important during activation of
the inflammatory response against bacterial infection for
example [24]. Th17 cells have an opposite function to
Treg cells (especially iTreg cells) in relation to Th1 andTh2 cells. Interestingly, TGF-β in the presence of IL-6
induced the development of Th17 cells from naïve T
cells whereas TGF-β alone induced the development of
CD4+CD25+Foxp3+ Treg cells [25,26]. Mouse Th17 cells
produce large amounts of IL-17, but no IL-4, IFN-γ or
Foxp3 and contribute to airway hyper-responsiveness
[25,27]. Several studies showed a possible involvement
of Th17 cells in the pathogenesis of asthma. The number
of IL-17 positive cells in sputum and BAL as well as the
expression of mRNA for IL-17 in sputum cells is in-
creased in asthma [28,29]. The levels of IL-17 in sputum
correlated with hyperresponsiveness to methacholine in
asthmatic subjects [30]. Increased levels of IL-17 in spu-
tum were also seen in patients with allergic rhinitis after
a nasal allergen challenge [31]. Interestingly, two recent
reports showed the opposite results [32,33]. In the first
study an increased expression of IL-17 in the bronchial
epithelium was observed in severe asthma but not in
mild or moderate asthma [32] whereas increased ex-
pression of IL-17 was reported in mild-moderate, but
not severe asthma, in the second study [33].
In this study we isolated CD4+ cells from BAL fluid of
asthmatics and age-matched control subjects and after
short in vitro stimulation we measured simultaneously
the expression of up to six parameters in these cells:
– set 1: TGF-β, FoxP3, CD25, IFN-γ, IL-4, TNF-α;
– set 2: IL-10, FoxP3, CD25, IFN-γ, IL-4, MIP-1β;
– set 3: IL-17A, IL-8, IFN-γ, IL-4, MIP-1β.
The aim of our study was to analyze the incidence of dif-
ferent subsets of CD4+ T cells in BAL fluid of asthmatics
and healthy subjects, in particular CD4+CD25+Foxp3+ cells,
CD4+Foxp3+ cells, CD4+IL-10+IL-4- cells, CD4+TGF-β+
cells, CD4+TGF-β+Foxp3+ cells and CD4+IL-17+ cells
together with the co-expression of various cytokines:
IFN-γ - a marker of Th1 cells, IL-4 – a marker of Th2
cells, IL-8 (CXCL8) – a chemokine for neutrophils, MIP-1β
(CCL4) – a chemokine for monocytes and macrophages
and TNF-α - a proinflammatory cytokine.
Materials and methods
Subjects
The study protocol was approved by the ethics commit-
tee of the Silesian Medical University. All subjects gave
written consent before recruitment to the study. Twenty
five stable asthmatic patients with a median age of
50 years (range 24–69 years) were recruited to the study.
The inclusion criteria were as follow: the presence of
consistent history of asthma together with objective evi-
dence of asthma such as: reversible of airflow obstruc-
tion (improvement in FEV1 greater than 12% or 200 ml
15 minutes after administration of 200 μg of inhaled sal-
butamol) or airway hyperresponsiveness to methacholine
Table 2 The sets of antibodies used in the study
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steroids (100–1000 μg/day of fluticasone or equivalent).
The control group consisted of 12 non atopic age-
matched healthy subjects with a median age of 42 years
(range 26–62 years) with no history of any respiratory
disease and no evidence of variable airflow obstruction
or airway hyperresponsiveness.
The exclusion criteria for both studied groups were re-
spiratory infection or use of oral corticosteroids within
6 weeks before entering the study. Current and ex-smokers
of >5 pack-years were also excluded from the study. Sub-
ject characteristics are shown in Table 1.
Bronchoscopy and BAL
The tip of the bronchoscope was wedged into the orifice
of a subsegmental bronchus of the middle lobe. Broncho-
alveolar lavage was done by sequential installation and
aspiration of 8 separate aliquots of 25 mL of warm 0.9%
normal saline.
Isolation of CD4+ T cells from BAL fluid
CD4+ T cells were isolated from BAL fluid as previously
described [34]. Briefly, BAL cells were spun, washed and
resuspended in culture medium (RPMI-1640, 10% [vol/
vol] FCS, 2 mM l-glutamine, 100 IU/mL penicillin, and
100 mg/mL streptomycin). Macrophages were depleted
from cells by means of adhesion to plastic plates. Resulting
nonadherent cells consisted mainly of lymphocytes, but
variable amounts of dead cells, granulocytes, and epithelial
cells were also present. Dead cells were eliminated with
the Dead Cell Removal Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany). Subsequently, CD8+ T cells were
removed by using MACS CD8+ MicroBeads (Miltenyi
Biotec). Finally CD4+ T cells were isolated by positive
selection using MACS CD4+ MicroBeads. The purity of
isolated CD4+ T cells were consistently >95% as assessed
by FACS.
Flow cytometry
CD4+ cells were washed and stimulated for 6 hours with
phorbol 12-myristate 13-acetate (PMA; 10 ng/mL) and
ionomycin (400 ng/mL) in the presence of brefeldin ATable 1 Characteristics of study subjects
Group Patients with asthma Control subjects
N 25 12
Age (y) 50 (24–69) 42 (26–62)
Sex (M/F) 8/17 10/2
FEV1 (% predicted) 86.6 (45.6–122.1)‡ 103.7 (95.1–123.5)
FEV1/FVC (%) 72.4 (48.9–87.4)‡ 85.6 (75.0–94.7)
Data are expressed as median (range).
M, Male; F, female; FEV1, forced expiratory volume in 1 sec; FVC, forced
vital capacity.
‡P < .001 compared with the control group.(5 mg/mL). Cells were then washed twice in wash buffer,
fixed in cold 4% formaldehyde, washed in PBS, and fro-
zen at -70°C for later use as described previously [34].
Subsequently, cells were thawed, washed, permeabilized,
washed again and stained with a cocktail of antibodies
(described in details in Table 2) or respective mouse isotype
control antibodies for 30 minutes at room temperature in
the dark (all antibodies were from BD Pharmingen, Oxford,
UK with exception for PE-labeled anti-TGF-β purchased at
IQ Products, Groningen, The Netherlands). After being
washed twice, the cells were resuspended in 1% formal-
dehyde in PBS and analyzed within 24 hours by means
of six-colour flow cytometry (FACSAria flow cytometer,
BD Biosciences). Representative plots of flow cytometric
analysis were shown in Additional file 1.
Statistical analysis
Statistical analysis was performed using software packages
(GraphPad Prism 5.0; Statistica 9.0). Data are presented as
median (95% confidence intervals) except where stated. A
Gaussian distribution was tested with D’Agostino and
Pearson omnibus normality test. Between-group compari-
sons were assessed using a Mann–Whitney U test for
non-parametric data. Regression analysis was performed
using the Spearman rank correlation test. P values of less
than 0.05 were accepted as significant.
Results
BAL cell characterization
The percentage of eosinophils in BAL fluid of asthmatics
was significantly higher compared to control subjects
(p < 0.01). Full characterisation of BAL cells is provided
in Table 3.
Percentage of BAL CD4+ cells expressing and
co-expressing Foxp3
The percentage of CD4+ cells co-expressing Foxp3 and
TGF-β (CD4+Foxp3+TGF-β+ cells) was significantly lower
in asthmatics [0.8% (0.1–4.2%)] compared with that seenFluorochrome Set Nr. 1 Set Nr. 2 Set Nr. 3
FITC Anti- IFN-γ Anti- IFN-γ Anti- IFN-γ
PE Anti- TGF-β Anti- FoxP3 Anti- IL-8
PerCP-Cy5.5 Anti- TNF-α Anti- MIP-1β Anti- MIP-1β
PE-Cy7 Anti- IL-4 Anti- IL-4 Anti- IL-4
APC or Alexa Fluor 647 Anti- FoxP3 Anti- IL-10 Anti- IL-17A
APC-Cy7 Anti- CD25 Anti- CD25
FITC - Fluorescein isothiocyanate; PE - R-phycoerythrin; PerCP-Cy5.5 - a tandem
fluorochrome composed of peridinin chlorophyll protein (PerCP) coupled to
the cyanine dye Cy5.5; PE-Cy7 - a tandem fluorochrome composed of
R-phycoerythrin (PE) coupled to the cyanine dye Cy7; APC - Allophycocyanin;
APC-Cy7 - a tandem fluorochrome composed of Allophycocyanin (APC)
coupled to the cyanine dye Cy7.
Table 3 Characteristics of BAL cells from the study
population
Group Patients with
asthma
Control
subjects
Recovery (ml) 122 (90–147) 123.5 (95–140)
Total cells number (×106) 3.9 (0.7–32.8) 5.0 (1.4–27.4)
Total cell number per volume
of BAL recovered (×104/ml)
3.0 (0.7–25.0) 4.1 (1.0–23.2)
Macrophages (%) 89.0 (41.5–97.8) 91.7 (82.7–98.7)
Neutrophils (%) 0.5 (0–3.9) 0.3 (0–1.7)
Eosinophils (%) 0.3 (0–10.0)† 0 (0–0.7)
Lymphocytes (%) 10.2 (1.8–57.3) 7.9 (1.3–16.4)
Data are expressed as median (range).
†P < .01 compared with the control group.
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In contract, there was no significant differences between
asthma and control groups in the percentage of CD4+
cells expressing Foxp3 (CD4+Foxp3+ cells) [4.4% (0.8–12.5%)
vs 6.8% (2.1–12.6%)], CD4+Foxp3+IFN-γ+ cells [2.1%
(0.3–5.6%) vs 1.8% (0.6–3.4%)], CD4+Foxp3+TNF-α+
cells [1.6% (0.4–4.3%) vs 1.8% (0.8–5.4%)], CD4+Foxp3+
IL-4+ cells [1.9% (0.2–8.7%) vs 1.6% (0.4–4.2%)], CD4+
Foxp3+IL-10+ cells [2.0% (0.1–7.5%) vs 1.1% (0.3–5.7%)]
or CD4+Foxp3+CD25+ cells [2.3% (0.1–10.7%) vs 2.6%
(0.7–4.3%)].as
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Figure 1 Percentage of BAL CD4+ cells expressing and co-expressing
and TGF-β (CD4+Foxp3+TGF-β+ cells), (B) CD4+Foxp3+ BAL cells expressing
BAL cells expressing CD25.A significantly higher percentage of CD4+Foxp3+ cells
from asthma patients compared with healthy subjects
expressed IFN-γ [42.6% (25.4–71.2%) vs 29.1% (16.2–
44.4%); Figure 1B; P = 0.01], IL-4 [48.8% (13.4–77.4%) vs
26.3% (16.7–43.6%); Figure 1C; P = 0.004] and CD25
[51.3% (11.9–88.1%) vs 35.1% (13.2–72.5%); Figure 1D;
P = 0.04). In contrast, no significant difference between
the studied groups were observed for the percentage of
CD4+Foxp3+ cells expressing TGF-β [18.2% (4.9–49.3%)
vs 25.7% (11.4–46.5%)], IL-10 [35.9% (3.6–61.5%) vs 19.6%
(3.3–52.5%); P = 0.07] or TNF-α [33.7% (10.9–80.9%) vs
33.0% (11.0–66.7%)].
Percentage of BAL CD4+ cells expressing and
co-expressing TGF-β
The percentage of CD4+TGF-β+ cells [3.0% (0.5–11.6%)
vs 4.1% (0.7–12.9%)], CD4+TGF-β+CD25+ cells [0.4%
(0–1.8%) vs 0.5% (0.1–1.7%)], CD4+TGF-β+IL-4+ cells
[0.5% (0.1–2.7%) vs 0.4% (0–2.8%)], CD4+TGF-β+IFN-γ+
cells [1.6% (0.3–5.9%) vs 1.4% (0.2–5.1%)] or CD4+TGF-
β+TNF-α+ cells [2.2% (0.3–4.9%) vs 1.2% (0.3–4.4%)]
did not significantly differ between asthma and control
groups.
CD4+TGF-β+ cells from asthmatics compared with
healthy subjects expressed significantly more IFN-γ
[61.7% (11.4–82.9%) vs 40.3% (15.4–55.5%); Figure 2A;
P = 0.004] and TNF-α [54.6% (10.4–79.5%) vs 40.7%as
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Foxp3. The percentage of (A) BAL CD4+ cells co-expressing Foxp3
IFN-γ, (C) CD4+Foxp3+ BAL cells expressing IL-4 and (D) CD4+Foxp3+
as
thm
a
co
ntr
ol
0
20
40
60
80
100
p=0.004
%
 
o
f C
D4
+
TG
F 
 
+
 
c
e
lls
 
e
x
pr
e
s
s
in
g 
IF
N
as
thm
a
co
ntr
ol
0
20
40
60
80
100
p=0.01
%
 
o
f C
D4
+
TG
F 
 
 
+
 
c
e
lls
 
e
x
pr
e
s
s
in
g 
TN
F
as
thm
a
co
ntr
ol
0
20
40
60
80
p=0.03
%
 
o
f C
D4
+
IL
10
+
 
c
e
lls
 
e
x
pr
e
s
s
in
g 
Fo
xp
3
A B
C
Figure 2 Percentage of BAL CD4+ cells expressing and co-expressing TGF-β or IL-10. The percentage of BAL CD4+TGF-β+ cells expressing
(A) IFN-γ and (B) expressing TNF-α. (C) The percentage of BAL CD4+IL-10+ cells expressing Foxp3.
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http://www.journal-inflammation.com/content/11/1/22(20.2–72.2%); Figure 2B; P = 0.01]. The expression of
Foxp3 [28.1% (4.9–61.0%) vs 36.4% (13.7–52.9%)],
CD25 [14.3% (0–28.8%) vs 14.9% (7.9–28.9%)] or IL-4
[16.9% (3.5–37.3%) vs 10.7% (0–34.0%)] in CD4+TGF-β+
cells did not differ significantly between asthma and
control groups.Percentage of BAL CD4+ cells expressing and
co-expressing IL-10
There were no significant difference between asthmatics
and healthy subjects concerning the percentage of CD4+IL-
10+IL-4- cells [1.6% (0.2–4.0%) vs 1.3% (0.4–9.5%)],
CD4+IL-10+ cells [3.6% (0–18.6%) vs 3.8% (0.9–14.3%)],
CD4+IL-10+CD25+ cells [1.6% (0.1–15.9%) vs 1.6%
(0.7–9.0%)], CD4+IL-10+IL-4+ cells [1.8% (0.1–7.2%) vs
1.1% (0.3–1.7%)], CD4+IL-10+ IFN-γ+ cells [1.6% (0–
7.8%) vs 1.0% (0.3–3.6%)] or CD4+IL-10+MIP-1β+ cells
[1.8% (0.1–7.2%) vs 1.1% (0.3–1.7%)]. In contrast, the
percentage of CD4+IL-10+ cells expressing Foxp3 was
significantly decreased in asthmatics compared with healthy
subjects [16.9% (4.8–66.7%) vs 31.3% (4.1–62.2%);
Figure 2C; P = 0.03]. No differences between the two
groups were observed for the expression of CD25 [54.0%
(13.1–95.0%) vs 62.9% (21.5–77.5%)], IL-4 [56.7% (11.5–
92.2%) vs 52.3% (22.8–71.7%)], IFN-γ [37.4% (2.4–72.4%)
vs 29.1% (7.2–71.2%)] or MIP-1β [39.1% (12.1–76.5%) vs
24.0% (11.9–65.2%)] in CD4+IL-10+ cells.Percentage of BAL CD4+ cells expressing and
co-expressing IL-17A
The percentage of CD4+IL-17+ cells [4.6% (1.2–14.4%)
vs 2.2% (0.5–7.7%); Figure 3A; P = 0.008] and CD4+IL-17+
IFN-γ+ cells [2.1% (0.3–8.4%) vs 1.0% (0.2–3.4%);
Figure 3B; P = 0.047] were significantly increased in asth-
matics compared with that seen in healthy subjects. No
significant differences between the two groups were ob-
served for the percentage of CD4+IL-17+IL-8+ cells [1.4%
(0.2–7.5%) vs 0.8% (0.2–2.2%); P = 0.09], CD4+IL-17+MIP-
1β+ cells [1.6% (0.2–7.5%) vs 0.5% (0.1–4.1%); P = 0.07] or
CD4+IL-17+IL-4+ cells [0.5% (0–2.5%) vs 0.3% (0.1–0.6%)].
Similarly, the percentage of CD4+IL-17+ cells expressing
IFN-γ [50.0% (22.7–65.6%) vs 44.4% (33.6–68.3%)], IL-8
[36.5% (15.8–72.3%) vs 31.9% (12.7–72.1%)], IL-4 [10.1%
(0–33.3%) vs 9.3% (1.4–37.5%)] or MIP-1β [33.5% (5.7–
75.3%) vs 32.6% (14.1–68.6%)] did not differ between the
two groups.
Percentage of BAL CD4+ cells expressing other cytokines
and markers
Significantly increased percentage of CD4+ cells express-
ing IL-4 (CD4+IL-4+ cells) was seen in asthma patients
[6.1% (0–32.3%)] compared with healthy subjects [2.8%
(1.5–6.6%), Figure 3C; P = 0.01]. No further statistically
significant differences concerning the percentage of CD4+
cells expressing IFN-γ [19.2% (7.3–49.8%) vs 17.0% (4.8–
29.8%)], IL-8 [9.7% (1.0–23.4%) vs 9.4% (3.2–17.4%)],
as
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Figure 3 Percentage of BAL CD4+ cells expressing and co-expressing IL-17A or IL-4. The percentage of BAL (A) CD4+ cells expressing IL-17
(CD4+IL-17+ cells), (B) CD4+ cells co-expressing IL-17 and IFN-γ (CD4+IL-17+ IFN-γ+ cells) and (C) CD4+ cells expressing IL-4 (CD4+IL-4+ cells).
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http://www.journal-inflammation.com/content/11/1/22TNF-α [29.8% (2.5–75.2%) vs 15.4% (3.3–58.3%)], MIP-1β
[11.8% (1.1–58.5%) vs 9.7% (2.6–33.4%)] or CD25 [4.3%
(0.4–17.5%) vs 4.9% (1.7–16.3%)] were observed between
asthma and control groups.
Correlation between different subtypes of CD4+ cells and
spirometry results or the percentage of BAL cells
The percentage of CD4+IL-17+ cells correlated negatively
with FEV1% predicted (r = -0.33; P < 0.05; Figure 4A),
whereas the percentage of CD4+Foxp3+ cells showed a
positive correlation with FEV1/FVC (r = 0.39; P < 0.05).
Similarly, CD4+Foxp3+TGF-β+ cells correlated positively
with FEV1% predicted (r = 0.43; P < 0.05; Figure 4B) and
FEV1/FVC (r = 0.57; P < 0.05) but negatively with ther = -.33; P = .046
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P < 0.05), the number of CD4+ cells (r = -0.53; P < 0.05)
and the number of CD8+ cells (r = -0.62; P < 0.05) in
BAL fluid. We also observed that the percentage of
CD4+TGF-β+CD25+ cells correlated negatively with
the number of CD4+ cells (r = -0.39; P < 0.05) and the
number of CD8+ cells (r = -0.44; P < .05) in BAL fluid.
Discussion
In this study we analyzed the incidence of different sub-
sets of CD4+ T cells together with the co-expression of
various cytokines in BAL fluid of asthma patients and
healthy subjects. We found that in BAL fluid of patients
with chronic asthma have a decreased population ofr = .43; P = .01
30 80 130
0
1
2
3
4
5
FEV1 % of predicted
%
 
o
f C
D4
+
ce
lls
ex
pr
es
si
n
g 
Fo
x
p3
+
 
an
d 
TG
F+
B
irometry results or the percentage of BAL cells. A. CD4+IL-17+ cells
Barczyk et al. Journal of Inflammation 2014, 11:22 Page 7 of 9
http://www.journal-inflammation.com/content/11/1/22CD4+Foxp3+TGF-β+ cells and at the same time an in-
creased population of CD4+IL-17+ cells, CD4+IL-17+
IFN-γ+ cells and CD4+IL-4+ cells. We also found that
decreasing FEV1 correlated with the decreasing percent-
age of CD4+Foxp3+TGF-β+ cells and simultaneously
with the increasing percentage numbers of CD4+IL-17+
cells. Additionally, CD4+Foxp3+ cells derived from the
BAL fluid of asthmatics were characterized by an increased
expression of IFN-γ, IL-4 and CD25, whereas CD4+IL-10+
cells had a decreased expression of Foxp3.
Our study is the first to show the decreased population
of CD4+Foxp3+TGF-β+ cells in BAL fluid of asthma pa-
tients. We did not observe a significant difference be-
tween asthma and controls with respect to the incidence
of other Foxp3 or IL-10 positive cells: CD4+Foxp3+,
CD4+Foxp3+CD25+, CD4+IL-10+IL-4- or CD4+Foxp3+IL-
10+. Therefore the results of our study do not confirm ei-
ther the recent report of Smith et al., who showed increased
percentage of CD4+Foxp3+ and CD4+CD25+CD127- cells
in BAL fluid of moderate to severe asthma [22] or the
results of Hartl et al. who found a decreased percentage of
CD4 +CD25high cells in BAL fluid of pediatric asthma pa-
tients [20]. Hartl and colleagues also found that the sup-
pressive capacity of CD4 + CD25high cells in BAL fluid
was depended on TGF-β, so they speculated that these
cells may represent iTreg cells. The results of our study
are therefore much closer to those of Hartl et al. as we
showed a decreased percentage of CD4+Foxp3+TGF-β+
cells in BAL fluid of asthma patients. Similarly, we
speculate that this subset of T cells may represent Th3
iTreg cells as these cells express TGF-β. Additionally,
the percentage of CD4+Foxp3+CD25+ did not differ between
the two groups studied.
Asthma is an inflammatory disease of a peripheral
organ, the lung, so the involvement of locally-induced
iTreg cells instead of nTreg cells in the pathogenesis of
this disease seems to be more probable. The decreased
population of Th3 iTreg cells may, therefore, contribute
to the presence of airway inflammation and to asthma
progression since there is a correlation between the per-
centage of CD4+Foxp3+TGF-β+ cells and FEV1.
Although several studies have previously shown the
importance of IL-17 and IL-17 producing cells in asthma
pathogenesis our study is, to our knowledge, the first to
show using flow cytometry and intracellular cytokine
staining that the percentage of CD4+IL-17+ cells in BAL
fluid of asthma patients is increased. Th17 cells are known
inducers of neutrophilic inflammation as they stimulate
other cells (e.g. epithelial cells) to produce IL-8/CXCL8,
which is one of the most potent neutrophil chemoatrac-
tants [2]. In this study we showed that CD4+IL-17+ cells
in humans are able to produce IL-8/CXCL8, but we ob-
served no differences in the percentage of CD4+IL-17+IL-
8+ cells between asthmatic and control groups. Th17 cellsmay also cooperate with Th2 cells to induce eosinophilic
airway inflammation in mice [35]. In our study we con-
firmed an increased population of Th2 cells, which may
indicate that Th17 and Th2 may work together to play an
important role in the pathogenesis of human asthma.
The role of CD4+IL-17+ cells in pathogenesis of asthma
is further supported by the presence of a negative correl-
ation with FEV1. Interestingly, approximately half of the
CD4+IL-17+ cells in our study expressed INF-γ+ and the
percentage of these CD4+IL-17+INF-γ+ cells was signifi-
cantly increased in asthma (P = 0.047). Th17 cells show
great degree of plasticity and during the inflammatory
response Th17/Th1 cells can be readily detected [36] in-
dicating a close relationship between Th1 and Th17 cell
differentiation programs [37,38]. Our results suggest
therefore that part of increased activity of Th17 cells in
asthma could be attributed to Th17/Th1 cells.
Although we observed no difference in the percentage
of CD4+IL-10+, CD4+IL-10+IL-4- or CD4+IL-10+Foxp3+
cells between the asthma and control groups, we found
that CD4+IL-10+ cells of asthmatics expressed less Foxp3.
Many studies have shown that IL-10-secreting Treg cells
(Tr1) generally do not express Foxp3, but IL-10-secreting
Foxp3+CD4+ cells have also been reported by others. Our
findings suggest therefore that Foxp3- IL-10-secreting
CD4+ cells predominate in asthmatic patients.
Increased expression of IFN-γ and IL-4 by CD4+Foxp3+
cells will suppress the immune response in asthmatic pa-
tients. nTreg are poor producers of proinflammatory cyto-
kines such as IL-4, IFN-γ or IL-17 [17]. However, recent
studies indicate that a subset of CD4+Foxp3+ cells in
humans are not regulatory but effector CD4+ cells [39-41].
It may be possible, therefore, that CD4+Foxp3+ cells ex-
pressing IFN-γ or IL-4 represent activated effector CD4+
cells. Alternatively, since iTreg cells show much higher
level of plasticity than nTreg cells [37,38] and are able to
transform into CD4+Foxp3+IL-17+ cells in the presence of
an inflammatory cytokine milieu [42]. A similar conver-
sion of Foxp3+ Treg cells into effector cells secreting IL-4
or IFN-γ has been observed and these cells were able to
express low levels of Foxp3 [43,44]. It may therefore pos-
sible that a subset of CD4+Foxp3+ cells expressing IL-4 or
IFN-γ cells are iTreg cells. Additionally, the increased
population of CD4+Foxp3+IFN-γ+ and CD4+Foxp3+IL-4+
cells in asthmatics suggest that CD4+Foxp3+ cells in those
patients are very plastic and depending on different cir-
cumstances may show different phenotypes.
In conclusion, our results suggest that in the airways
of chronic asthma patients there is an imbalance be-
tween the increased population of CD4+IL-17+ cells,
CD4+IL-17+IFN-γ+ cells and CD4+IL-4+ cells and the
decreased population of CD4+Foxp3+TGF-β+ cells. This
imbalance may be important for development of airway
obstruction in asthma as we found that decreased FEV1
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TGF-β+ cells and simultaneously with the increasing
percentage numbers of CD4+IL-17+ cells.
Additional file
Additional file 1: Figure S1. Representative plots of flow cytometric
analysis. (A) BAL CD4+ cells expressing or co-expressing TGF-β or Foxp3
from asthma patient. (B) BAL CD4+ cells expressing or co-expressing
TGF-β or Foxp3 from control subject. (C) BAL CD4+ cells expressing or
co-expressing IFN-γ or IL-17 from asthma patient. (D) BAL CD4+ cells
expressing or co-expressing IFN-γ or IL-17 from control subject. Cells were
stimulated with PMA/ionomycin for 6 hrs in the presence of Brefeldin A.
The plots are representative of those from 25 asthmatic and 12 healthy
control subjects.
Abbreviations
BAL: Bronchoalveolar lavage; CCL4: CC chemokine ligand 4; CD: Cluster of
differentiation; CXCL8: CXC chemokine ligand 8; FCS: Fetal calf serum;
FEV1: Forced expiratory volume in 1 second; FoxP3: Forkhead box P3;
FVC: Forced vital capacity; IFN-γ: Interferon-γ; IL: Interleukin; iTreg: Inducible T
regulatory; MIP-1β: Macrophage inflammatory protein-1β; nTreg: Natural T
regulatory; PC20: Provocative concentration causing a 20% fall in FEV1;
PMA: Phorbol 12-myristate 13-acetate; TGF-β: Tranforming growth factor-β;
Th: T helper; TNF-α: tumor necrosis factor-α; Tr1: T regulatory type 1; Treg: T
regulatory.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
AB, WP, MK, PJB, IMA defined the research theme; AB, WP, IMA designed the
study, AB, GC, RW, IMA designed methods and experiments, AB, WP,
collected subjects’ samples, AB, RW, carried out the laboratory experiments,
AB, WP, RW, MK, IMA participated in analysis of data, AB, GC, MK, IMA
performed the statistical analysis, AB, WP, RW, PJB, IMA interpreted the
results, and AB, WP, GC, RW, MK, PJB, IMA wrote the paper. All authors read
and approved the manuscript.
Acknowledgments
The authors thank Izabela Santura and Ewa Sozanska for technical assistance.
This work was supported by Polish Ministry of Science, Grant Nr N402
009 32/0195 and grants from the MRC (G0801266) and Wellcome Trust
(093080/Z/10/Z) to IMA and PJB.
Author details
1Katedra i Klinika Pneumonologii, Slaski Uniwersytet Medyczny w Katowicach,
Katowice, Poland. 2Centro Interdipartimentale per lo Studio delle Malattie
Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly
Centro di Ricerca su Asma e BPCO), Sezione di Malattie dell’Apparato
Respiratorio, Università di Ferrara, Ferrara, Italy. 3Katedra i Zaklad Histologii i
Embriologii, Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland.
4Airway Disease Section, National Heart and Lung Institute, Imperial College
London, Dovehouse Street, London SW3 6LY, UK.
Received: 11 February 2014 Accepted: 28 June 2014
Published: 9 August 2014
References
1. Global Strategy for Asthma Management and Prevention. Global
Initiative for Asthma (GINA). 2011. Available from [www.ginasthma.org]
Date last updated. 2011.
2. Barnes PJ: The cytokine network in asthma and chronic obstructive
pulmonary disease. J Clin Invest 2008, 118:3546–3556.
3. Barnes PJ: Immunology of asthma and chronic obstructive pulmonary
disease. Nat Rev Immunol 2008, 8:183–192.
4. Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat
Rev Immunol 2003, 3:253–257.5. Kraszula L, Eusebio MO, Kupczyk M, Kuna P, Pietruczuk M: [The use of
multi-color flow cytometry for identification of functional markers of
nTregs in patients with severe asthma]. Pneumonol Alergol Pol 2012,
80:389–401.
6. Corthay A: How do regulatory T cells work? Scand J Immunol 2009,
70:326–336.
7. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ: All-trans retinoic acid
mediates enhanced T reg cell growth, differentiation, and gut homing in
the face of high levels of co-stimulation. J Exp Med 2007, 204:1765–1774.
8. McGee HS, Agrawal DK: Naturally occurring and inducible T-regulatory
cells modulating immune response in allergic asthma. Am J Respir Crit
Care Med 2009, 180:211–225.
9. Horwitz DA, Zheng SG, Gray JD: Natural and TGF-beta-induced Foxp3(+)
CD4(+) CD25(+) regulatory T cells are not mirror images of each other.
Trends Immunol 2008, 29:429–435.
10. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA: Natural and induced
CD4 + CD25+ cells educate CD4+. J Immunol 2004, 172:5213–5221.
11. Li MO, Sanjabi S, Flavell RA: Transforming growth factor-beta controls
development, homeostasis, and tolerance of T cells by regulatory T
cell-dependent and -independent mechanisms. Immunity 2006, 25:455–471.
12. Carrier Y, Yuan J, Kuchroo VK, Weiner HL: Th3 cells in peripheral tolerance.
I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from
TGF-beta T cell-transgenic mice. J Immunol 2007, 178:179–185.
13. Gordon ED, Sidhu SS, Wang ZE, Woodruff PG, Yuan S, Solon MC, Conway SJ,
Huang X, Locksley RM, Fahy JV: A protective role for periostin and
TGF-beta in IgE-mediated allergy and airway hyperresponsiveness.
Clin Exp Allergy 2012, 42:144–155.
14. Fujio K, Okamura T, Yamamoto K: The family of IL-10-secreting CD4+ T
cells. Adv Immunol 2010, 105:99–130.
15. Vieira PL, Christensen JR, Minaee S, O’Neill EJ, Barrat FJ, Boonstra A, Barthlott T,
Stockinger B, Wraith DC, O’Garra A: IL-10-secreting regulatory T cells do not
express Foxp3 but have comparable regulatory function to naturally
occurring CD4 + CD25+ regulatory T cells. J Immunol 2004, 172:5986–5993.
16. Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N: Cutting
edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells.
J Immunol 2008, 180:2752–2756.
17. Miyara M, Wing K, Sakaguchi S: Therapeutic approaches to allergy and
autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.
J Allergy Clin Immunol 2009, 123:749–755.
18. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY,
Weaver CT: Regulatory T cells expressing interleukin 10 develop from
Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10.
Nat Immunol 2007, 8:931–941.
19. Li X, Yang A, Huang H, Zhang X, Town J, Davis B, Cockcroft DW, Gordon JR:
Induction of type 2 T helper cell allergen tolerance by IL-10-differentiated
regulatory dendritic cells. Am J Respir Cell Mol Biol 2010, 42:190–199.
20. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, Griese M,
Krauss-Etschmann S: Quantitative and functional impairment of pulmonary
CD4+ CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol
2007, 119:1258–1266.
21. Provoost S, Maes T, van Durme YM, Gevaert P, Bachert C, Schmidt-Weber CB,
Brusselle GG, Joos GF, Tournoy KG: Decreased FOXP3 protein expression in
patients with asthma. Allergy 2009, 64:1539–1546.
22. Smyth LJ, Eustace A, Kolsum U, Blaikely J, Singh D: Increased airway T
regulatory cells in asthmatic subjects. Chest 2010, 138:905–912.
23. Thunberg S, Gafvelin G, Nord M, Gronneberg R, Grunewald J, Eklund A,
van Hage M: Allergen provocation increases TH2-cytokines and FOXP3
expression in the asthmatic lung. Allergy 2010, 65:311–318.
24. Akdis M, Palomares O, van de Veen W, van Splunter M, Akdis CA: TH17 and
TH22 cells: a confusion of antimicrobial response with tissue inflammation
versus protection. J Allergy Clin Immunol 2012, 129:1438–1449.
25. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO,
Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth
factor-beta induces development of the T(H)17 lineage. Nature 2006,
441:231–234.
26. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK:
Reciprocal developmental pathways for the generation of pathogenic
effector TH17 and regulatory T cells. Nature 2006, 441:235–238.
27. Kudo M, Melton AC, Chen C, Engler MB, Huang KE, Ren X, Wang Y,
Bernstein X, Li JT, Atabai K, Huang X, Sheppard D: IL-17A produced by
alphabeta T cells drives airway hyper-responsiveness in mice and
Barczyk et al. Journal of Inflammation 2014, 11:22 Page 9 of 9
http://www.journal-inflammation.com/content/11/1/22enhances mouse and human airway smooth muscle contraction.
Nat Med 2012, 18:547–554.
28. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J,
Chakir J: IL-17 is increased in asthmatic airways and induces human
bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001,
108:430–438.
29. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ,
Ceuppens JL: IL-17 mRNA in sputum of asthmatic patients: linking T cell
driven inflammation and granulocytic influx? Respir Res 2006, 7:135.
30. Barczyk A, Pierzchala W, Sozanska E: Interleukin-17 in sputum correlates
with airway hyperresponsiveness to methacholine. Respir Med 2003,
97:726–733.
31. Semik-Orzech A, Barczyk A, Wiaderkiewicz R, Pierzchala W: Interleukin 17
and RANTES levels in induced sputum of patients with allergic rhinitis
after a single nasal allergen challenge. Ann Allergy Asthma Immunol 2009,
103:418–424.
32. Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Lemiere C,
Hamid Q: T(H)17-associated cytokines (IL-17A and IL-17 F) in severe
asthma. J Allergy Clin Immunol 2009, 123:1185–1187.
33. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M,
Woods J, May R, Sleeman MA, Anderson IK, Brightling CE: Expression of the
T helper 17-associated cytokines IL-17A and IL-17 F in asthma and
COPD. Chest 2010, 138:1140–1147.
34. Barczyk A, Pierzchala W, Kon OM, Cosio B, Adcock IM, Barnes PJ: Cytokine
production by bronchoalveolar lavage T lymphocytes in chronic
obstructive pulmonary disease. J Allergy Clin Immunol 2006,
117:1484–1492.
35. Wakashin H, Hirose K, Maezawa Y, Kagami S, Suto A, Watanabe N, Saito Y,
Hatano M, Tokuhisa T, Iwakura Y, Puccetti P, Iwamoto I, Nakajima H: IL-23
and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation
in mice. Am J Respir Crit Care Med 2008, 178:1023–1032.
36. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E,
Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E,
Romagnani S: Phenotypic and functional features of human Th17 cells. J Exp
Med 2007, 204:1849–1861.
37. Zhou L, Chong MM, Littman DR: Plasticity of CD4+ T cell lineage
differentiation. Immunity 2009, 30:646–655.
38. Peck A, Mellins ED: Plasticity of T-cell phenotype and function: the T
helper type 17 example. Immunology 2010, 129:147–153.
39. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE: Transient
expression of FOXP3 in human activated nonregulatory CD4+ T cells.
Eur J Immunol 2007, 37:129–138.
40. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R,
Roncarolo MG, Levings MK: Activation-induced FOXP3 in human T
effector cells does not suppress proliferation or cytokine production.
Int Immunol 2007, 19:345–354.
41. Tran DQ, Ramsey H, Shevach EM: Induction of FOXP3 expression in naive
human CD4 + FOXP3 T cells by T-cell receptor stimulation is transforming
growth factor-beta dependent but does not confer a regulatory
phenotype. Blood 2007, 110:2983–2990.
42. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, Valmori D:
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively
express the T(H)17 lineage-specific transcription factor RORgamma t.
Proc Natl Acad Sci U S A 2009, 106:8635–8640.
43. Williams LM, Rudensky AY: Maintenance of the Foxp3-dependent
developmental program in mature regulatory T cells requires continued
expression of Foxp3. Nat Immunol 2007, 8:277–284.
44. Wan YY, Flavell RA: Regulatory T-cell functions are subverted and converted
owing to attenuated Foxp3 expression. Nature 2007, 445:766–770.
doi:10.1186/1476-9255-11-22
Cite this article as: Barczyk et al.: Decreased percentage of CD4+Foxp3+TGF-β+
and increased percentage of CD4+IL-17+ cells in bronchoalveolar lavage of
asthmatics. Journal of Inflammation 2014 11:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
